Market Overview

Fasting Mimicking Diet® Is Awarded First-Ever Patent for Optimizing Human Healthspan

Share:

L-Nutra is disrupting the health industry with a method for promoting
tissue regeneration, longevity, better health

On July 10, L-Nutra,
Inc.
became the first company to market a product that has been
granted a patent by the United
States Patent and Trademark Office (USPTO)
for optimizing human
healthspan, the length of time that a person is healthy. This follows a
landmark patent issued in 2016 for treating diabetes and multiple
patents previously issued for cancer treatment, but this is the first
patented protocol to address health and wellness prior to the onset of
disease. The patent is for the Fasting Mimicking Diet® (FMD®),
discovered and clinically tested by the laboratory
of Valter Longo
and Keck
Hospital
at the University of Southern California (USC), a nutrition
technology that is proven to reduce markers for age-related disease as
well as promote tissue regeneration.

Fasting has always been part of human history; but recently, humans have
become accustomed to eating multiple times a day, every day, causing a
worldwide obesity epidemic. Over 70% of Americans are overweight or
obese. Carrying excess fat accelerates the aging process and often leads
to the early onset of diabetes, cancer, cardiovascular disease, and
Alzheimer's. Water-only fasting is an effective way to prevent obesity;
however, the most effective regimen consists of several consecutive days
without food, which is not only very difficult to comply with, but could
pose health challenges and side effects if done outside of a specialized
clinic. FMD protocols allow people to nourish their body with food while
keeping the body in "fasting mode." The current embodiment of the patent
is ProLon®,
a five-day FMD designed to minimize side effects and hunger thus making
periodic fasting easy, effective, and safe. It is also currently being
tested for positive effects that are even superior to those of
water-only fasting.

The patent distinguishes the Fasting Mimicking Diet from other diets in
its ability to promote tissue regeneration. This is critical because the
majority of diets only impact fat metabolism (e.g. weight loss), and the
fasting period of most forms of time-restricted eating (such as
intermittent fasting) are not sufficient to yield this effect. The FMD
positively stresses the body to induce major cellular benefits such as
autophagy (awarded the 2016 Nobel Prize in Medicine) and stem cell-based
regeneration. This regeneration and reset of the body could support
healthier aging by helping maintain body weight and improving physical
and mental performance in a way that takes advantage of natural human
evolution, tradition, and cutting-edge science.

"This is a milestone achievement for public health, and L-Nutra is proud
to be the first to market a product developed, tested, positioned, sold,
and now patented for optimizing longevity and healthspan," says Joseph
Antoun MD, CEO of L-Nutra. "L-Nutra's vision is to disrupt the current
‘sickcare' model of medicine and to advance the concept of healthy and
youthful longevity."

The Fasting Mimicking Diet is one of few nutri-technologies that has
undergone extensive scientific research and clinical trials at major
universities across the world. Last year, a landmark human trial
published in Science Translational Medicine demonstrated that
ProLon is clinically proven to reduce markers of the body's aging
process, optimize weight, and maintain healthy levels of multiple
metabolic markers such as cholesterol, triglyceride, glucose, and CRP
(an inflammatory marker). The secret to the Fasting Mimicking Diet
relies on the body's activation of the epigenetic, metabolic, and
cellular reprogramming to survive prolonged periods of fasting.

"At L-Nutra, we believe that by understanding and respecting nature,
tradition, and science, we can promote remarkable self repair and reset
mechanisms in the human body, which eventually may also be used to treat
and cure disease," adds Dr. Antoun. L-Nutra's plans include ongoing
university studies to develop additional types of Fasting Mimicking
Diets for addressing specific conditions such as multiple sclerosis,
diabetes, cancer, and Alzheimer's. For more information, please visit L-Nutra.com.

About L-Nutra, Inc.

L-Nutra's team of researchers and collaborators are leaders in the field
of nutrition related to longevity and healthspan. L-Nutra has the
exclusive rights from the University of Southern California to market
ProLon® and other FMD®s, which mimic and enhance the effects of fasting,
unleash the body's natural ability to rejuvenate itself, and promote
healthy longevity. These nutri-technologies are the result of decades of
lab and clinical research to demonstrate safety and efficacy. For more
information, please visit l-nutra.com
and prolonfmd.com.

View Comments and Join the Discussion!